Analysis and Evaluation of Personalized Medication Evidence Based on Pharmacogenetics
10.6039/j.issn.1001-0408.2016.08.01
- VernacularTitle:药物基因组学个体化用药证据基础分析与评价
- Author:
Yike WANG
;
Xu MA
;
Yuanyuan JIAO
;
Hong SHAO
;
Yanhua ZHANG
- Publication Type:Journal Article
- Keywords:
Pharmacogenetics;
Personalized medicine;
Literature analysis;
Evidence analysis;
Precision medicine
- From:
China Pharmacy
2016;27(8):1009-1012
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate evidence foundation of phamracogenetics personalized medication,and to provide refer-ence for clinical application. METHODS:Using“phamracogenetics”“pharmacogenomics”and“gene polymorphism”as key words,related literatures and clinical guideline were retrieved from PubMed,CNKI,Wanfang database,and analyzed in respects of involved gene,site and drug types,etc. Evidences of package inserts of phamracogenetics biomarker were evaluated by using phamracogenetics practice and prevention evaluation guideline. RESULTS:8 276 papers,25 guidelines and 166 drug package in-serts are available for analysis. The phamracogenetics literatures mostly focus on the relationship between some one gene and differ-ent drugs. In guidelines,some one specific gene can guide clinical application of multiple drugs in different fields. In drug package inserts,general level of clinical evidence is not high;detectable biomarkers is inadequate in category,and detection rate is only 38.06% besides targeting preparation. CONCLUSIONS:Under the condition of low clinical evidence level the detection of pharma-cogenetics biomarker should be conducted carefully,and basic study should be further strengthened.
